LED Corporation owns $1,000,000 of Branch Pharmaceuticals bonds and classifies its investment as securities available-for-sale. The market price of Branch’s bonds fell by $450,000 due to concerns about one of the company’s principal drugs. The concerns were justified when the FDA banned the drug. $100,000 of that decline in value already had been included in OCI as a temporary unrealized loss in a prior period. LED views $200,000 of the $450,000 loss as related to credit losses, and the other $250,000 as noncredit losses. LED does not plan to sell the investment and does not think it is more likely than not that it will have to sell the investment before fair value recovers. What journal entries should LED record to account for the decline in market value in the current period? How should the decline affect net income and comprehensive income? General Journal What journal entries should LED record to account for the decline in market value in the current period? Note: If no entry is required for a transaction/event, select "No journal entry required" in the first account field.     No Transaction General Journal Debit Credit 1 1 Credit loss expense  200,000       Allowance for credit losses    20,0 00           2 2 Loss on investments (unrealized, OCI) 250,000-wrong       Fair value adjustment   250,000 -wrong Effect How should the decline affect net income and comprehensive income? Note: Negative amounts should be entered with minus sign.         Effect Net income $(200,000) Other comprehensive income $(250,000)-wrong Net effect on comprehensive income $(450,000)-wrong

Intermediate Accounting: Reporting And Analysis
3rd Edition
ISBN:9781337788281
Author:James M. Wahlen, Jefferson P. Jones, Donald Pagach
Publisher:James M. Wahlen, Jefferson P. Jones, Donald Pagach
Chapter13: Investments And Long-term Receivables
Section: Chapter Questions
Problem 10RE: On September 30, Franz Corporation notices a decline in value of its investment in held-to-maturity...
icon
Related questions
Question

LED Corporation owns $1,000,000 of Branch Pharmaceuticals bonds and classifies its investment as securities available-for-sale. The market price of Branch’s bonds fell by $450,000 due to concerns about one of the company’s principal drugs. The concerns were justified when the FDA banned the drug. $100,000 of that decline in value already had been included in OCI as a temporary unrealized loss in a prior period. LED views $200,000 of the $450,000 loss as related to credit losses, and the other $250,000 as noncredit losses. LED does not plan to sell the investment and does not think it is more likely than not that it will have to sell the investment before fair value recovers.

What journal entries should LED record to account for the decline in market value in the current period? How should the decline affect net income and comprehensive income?

  • General Journal

What journal entries should LED record to account for the decline in market value in the current period?
Note: If no entry is required for a transaction/event, select "No journal entry required" in the first account field.

 
 
No Transaction General Journal Debit Credit
1 1 Credit loss expense  200,000  
    Allowance for credit losses    20,0 00
         
2 2 Loss on investments (unrealized, OCI) 250,000-wrong  
    Fair value adjustment   250,000 -wrong
  • Effect

How should the decline affect net income and comprehensive income?
Note: Negative amounts should be entered with minus sign.

 
 
 
  Effect
Net income $(200,000)
Other comprehensive income $(250,000)-wrong
Net effect on comprehensive income $(450,000)-wrong
Expert Solution
trending now

Trending now

This is a popular solution!

steps

Step by step

Solved in 4 steps

Blurred answer
Knowledge Booster
Accounting for Corporate restructuring
Learn more about
Need a deep-dive on the concept behind this application? Look no further. Learn more about this topic, accounting and related others by exploring similar questions and additional content below.
Similar questions
  • SEE MORE QUESTIONS
Recommended textbooks for you
Intermediate Accounting: Reporting And Analysis
Intermediate Accounting: Reporting And Analysis
Accounting
ISBN:
9781337788281
Author:
James M. Wahlen, Jefferson P. Jones, Donald Pagach
Publisher:
Cengage Learning